[go: up one dir, main page]

CY1110354T1 - Αναστολεις της μορφης μεταλλακτη του κιτ - Google Patents

Αναστολεις της μορφης μεταλλακτη του κιτ

Info

Publication number
CY1110354T1
CY1110354T1 CY20091100748T CY091100748T CY1110354T1 CY 1110354 T1 CY1110354 T1 CY 1110354T1 CY 20091100748 T CY20091100748 T CY 20091100748T CY 091100748 T CY091100748 T CY 091100748T CY 1110354 T1 CY1110354 T1 CY 1110354T1
Authority
CY
Cyprus
Prior art keywords
kit
suspensions
exchange format
kit exchange
mutant
Prior art date
Application number
CY20091100748T
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1110354T1 publication Critical patent/CY1110354T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη θεραπεία ασθενειών εξαρτώμενων από KIT που χαρακτηρίζονται από μία μορφή μεταλλάκτη KIT όπου ο μεταλλάκτης KIT προσδιορίζεται και χορηγείται ένας κατάλληλος αναστολέας του μεταλλάκτη KIT που επιλέγεται από μιδοσταουρίνη, βαταλανίβη και χορηγείται η ένωση Α.
CY20091100748T 2003-11-18 2009-07-14 Αναστολεις της μορφης μεταλλακτη του κιτ CY1110354T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
EP04818795A EP1686997B1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
CY1110354T1 true CY1110354T1 (el) 2015-04-29

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100748T CY1110354T1 (el) 2003-11-18 2009-07-14 Αναστολεις της μορφης μεταλλακτη του κιτ

Country Status (28)

Country Link
US (3) US8017621B2 (el)
EP (2) EP1686997B1 (el)
JP (3) JP4762150B2 (el)
KR (1) KR101153647B1 (el)
CN (3) CN102274230B (el)
AT (1) ATE428426T1 (el)
AU (1) AU2004290902B2 (el)
BR (1) BRPI0416680A (el)
CA (1) CA2546189C (el)
CY (1) CY1110354T1 (el)
DE (1) DE602004020654D1 (el)
DK (1) DK1686997T3 (el)
ES (1) ES2324917T3 (el)
HK (1) HK1093680A1 (el)
HR (1) HRP20090390T1 (el)
IL (2) IL175578A (el)
MA (1) MA28176A1 (el)
MX (1) MXPA06005598A (el)
NO (1) NO20062694L (el)
NZ (1) NZ547195A (el)
PL (1) PL1686997T3 (el)
PT (1) PT1686997E (el)
RU (2) RU2362562C2 (el)
SG (1) SG139747A1 (el)
SI (1) SI1686997T1 (el)
TN (1) TNSN06138A1 (el)
WO (1) WO2005049032A1 (el)
ZA (1) ZA200603905B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
EP1686997B1 (en) 2003-11-18 2009-04-15 Novartis AG Inhibitors of the mutant form of kit
AU2005279344B2 (en) * 2004-08-31 2009-11-12 Novartis Ag Use of midostaurin for treating gastrointestinal stromal tumors
MX2007013741A (es) 2005-05-02 2008-01-21 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica.
JP5154408B2 (ja) * 2005-05-02 2013-02-27 ノバルティス アーゲー 好酸球増加症候群のためのピリミジルアミノベンズアミド誘導体
ATE464911T1 (de) * 2005-07-20 2010-05-15 Peter Valent Zusammensetzungen zur behandlung von systemischer mastocytose
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR101498848B1 (ko) * 2005-12-06 2015-03-05 노파르티스 아게 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드 유도체
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
PT2237783E (pt) * 2008-01-23 2014-12-23 Novartis Ag Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib
US9801880B2 (en) 2013-12-02 2017-10-31 Bergenbio As Use of kinase inhibitors
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
TWI764186B (zh) 2018-06-15 2022-05-11 漢達生技醫藥股份有限公司 激酶抑制劑之鹽類及其組合物
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (el) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU692484B2 (en) * 1993-10-12 1998-06-11 Du Pont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ES2326500T3 (es) 1997-11-13 2009-10-13 Mowycal Lending, Llc Pequeños peptidos y metodos para el tratamiento del asma y la inflamacion.
US20040157855A1 (en) * 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
US20050054617A1 (en) 2001-06-29 2005-03-10 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
CN1625602A (zh) * 2002-03-13 2005-06-08 霍夫曼-拉罗奇有限公司 选择药物敏感性决定因子的方法和利用所选择的因子预测药物敏感性的方法
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005027971A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
EP1686997B1 (en) 2003-11-18 2009-04-15 Novartis AG Inhibitors of the mutant form of kit
MX2007013741A (es) 2005-05-02 2008-01-21 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica.
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
HRP20090390T1 (hr) 2009-08-31
EP1917965A1 (en) 2008-05-07
JP2007511567A (ja) 2007-05-10
RU2006121447A (ru) 2008-01-10
EP1686997B1 (en) 2009-04-15
AU2004290902A1 (en) 2005-06-02
NO20062694L (no) 2006-06-12
RU2362562C2 (ru) 2009-07-27
JP4762150B2 (ja) 2011-08-31
IL175578A (en) 2013-10-31
DK1686997T3 (da) 2009-07-27
IL229124A0 (en) 2013-12-31
MXPA06005598A (es) 2006-08-11
TNSN06138A1 (fr) 2007-11-15
IL175578A0 (en) 2008-04-13
CN1882344A (zh) 2006-12-20
RU2009110449A (ru) 2010-09-27
DE602004020654D1 (de) 2009-05-28
PT1686997E (pt) 2009-07-17
US20100179179A1 (en) 2010-07-15
US20070213317A1 (en) 2007-09-13
BRPI0416680A (pt) 2007-02-13
CN102274230A (zh) 2011-12-14
ES2324917T3 (es) 2009-08-19
JP2013241438A (ja) 2013-12-05
CA2546189A1 (en) 2005-06-02
ZA200603905B (en) 2008-11-26
ATE428426T1 (de) 2009-05-15
WO2005049032A1 (en) 2005-06-02
MA28176A1 (fr) 2006-09-01
US8017621B2 (en) 2011-09-13
KR20060101761A (ko) 2006-09-26
HK1093680A1 (en) 2007-03-09
KR101153647B1 (ko) 2012-06-18
EP1686997A1 (en) 2006-08-09
US20120157441A1 (en) 2012-06-21
CA2546189C (en) 2013-04-23
RU2405553C1 (ru) 2010-12-10
CN102274230B (zh) 2015-07-01
SG139747A1 (en) 2008-02-29
CN101693031A (zh) 2010-04-14
JP2011121973A (ja) 2011-06-23
NZ547195A (en) 2010-06-25
PL1686997T3 (pl) 2009-09-30
SI1686997T1 (sl) 2009-08-31
US8124611B2 (en) 2012-02-28
AU2004290902B2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
CY1110354T1 (el) Αναστολεις της μορφης μεταλλακτη του κιτ
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
NO20034056D0 (no) Proliferative sykdommer
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
DE60315368D1 (de) Korrektur des Weissabgleichs
EA200401114A3 (ru) Замещённые гидроксиэтиламины
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
BR0312446A (pt) 2-heteroaril carboxamidas
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
ECSP055844A (es) Nuevos compuestos triciclicos
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
EP1642969A4 (en) FLUORESCENCE PROTEIN AND PIGMENT PROTEIN
EA200100515A3 (ru) Диазепиноиндолы для лечения хронического обструктивного заболевания легких
DK1601352T3 (da) Kombineret anvendelse af et fibrat og orlistat til behandling af fedme
DK1670309T3 (da) Transgenetiske dyr med større lidelser i forbindelse med Alzheimers sygdom
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
DK1569650T3 (da) Anvendelse af levocetirizin til behandling af vedvarende rhinitis allergica
HN2001200000A (es) Suspension de ziprasidona
HN2001000126A (es) Derivados de 3-azabiciclo (3.1.0) hexano utiles en terapia
HN2002000006A (es) Utilizacion de cromanos
HN2003000228A (es) Derivados benzufurano y benzotiofeno utiles en el tratamiento de desordenes hiper - proliferativos